Downregulation or post-translational modification of these fusion proteins have been confirmed as related to a variety of heart diseases (Table 2), however, the specific mechanisms through which MFN1, MFN2, and OPA1 function in cardiomyocytes require further research. The gene discussed is OPA1; the disease is heart disorder.